Skip to main content
SpringerLink
Log in

Systemic chemotherapy combined with local adoptive immunotherapy cures rats bearing 9L gliosarcoma

  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Summary

Survival of Fischer rats bearing 9L gliosarcoma in the brain was measured to determine the efficacy of 1) systemically administered chemotherapy with local adoptive immunotherapy (chemo-adoptive immunotherapy) or 2) systemically administered chemo-immunotherapy. Winn assays, where tumor instillation coincided with the start of treatment, and one-week established tumor assays were conducted. Survival of chemo-adoptive immunotherapy treated groups given intraperitoneal cyclophosphamide and intracranial lymphokine activated killer cells and recombinant Interleukin-2 was significantly extended when compared to sham treated control groups, to groups given chemotherapy with intraperitoneal cyclophosphamide, and to groups treated by local adoptive immunotherapy with intracranial lymphokine activated killer cells and Interleukin-2. The killer cells were generated from spleens of donor rats that either had or had not been given cyclophosphamide 24 h earlier. Long-term survivors (9/39), sacrificed at day 70, were obtained only in the chemo-adoptive immunotherapy treated groups; 7/39 had no histologic evidence of tumor and had focal sterile abscesses at the site of killer cell instillation. Average group weight plotted over time showed that there was acceptable toxicity with chemo-adoptive immunotherapy; the toxicity was identical to that obtained with systemic cyclophosphamide treatment. In contrast, survival of chemo-immunotherapy treated groups given systemic cyclophosphamide and Interleukin-2 was not significantly extended from groups which were sham treated or treated only with systemic Interleukin-2. Rapid decline of average group weight plotted over time and early deaths following chemo-immunotherapy treatment indicated that the regimen was toxic. The effect of cyclophosphamide administration on the splenocytes of donor rats and the LAK cells generated from them was determined byin vitro studies analyzing cell number, viability, phenotypic expression and cytotoxicity against 9L tumor. In the treatment of this intracranial neoplasm, the beneficial effects of cyclophosphamide were determined to occurin situ in the tumor-bearing host. No benefit resulted from cyclophosphamide treatment of donor rats that supplied splenocytes for LAK cell production.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kornblith PL, Walker MD, Cassady JR: Treatment of patients with supratentorial tumors-astrocytomas, oligodendrogliomas and optic gliomas. In: Kornblith PL, Walter MD, Cassady JR (eds) Neurologic Oncology. J.B. Lippincott Company, Philadelphia, 1987, pp 117–154

    Google Scholar 

  2. Robb RJ, Kutney RM, Chowdry V: Purification and partial sequence analysis of human T cell growth factor. Proc Natl Acad Sci (USA) 80: 5590–5595, 1983

    Google Scholar 

  3. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA: The lymphokine activated killer cell phenomena: lysis of NK resistant fresh solid tumor cells by IL-2 activated autologous human peripheral blood lymphocytes. J Exp Med 155: 1823–1841, 1982

    Google Scholar 

  4. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avid FP, Leitman S, Linehan M, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson C, White DE: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. New Engl J Med 316: 889–897, 1987

    Google Scholar 

  5. Lillehei KO, Kruse CA, Mitchell DH, Johnson SD, McCleary EL: Adoptive immunotherapy of recurrent glioma using Interleukin-2 stimulated lymphocytes. Surgical Forum 40: 493–495, 1989

    Google Scholar 

  6. Lillehei KO, Mitchell DH, Johnson SD, McCleary EL, Kruse CA: Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy. Neurosurgery 28: 16–23, 1991

    Google Scholar 

  7. Jacobs SK, Wilson DJ, Kornblith PL, Grimm EA: Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma: phase I trial. Cancer Res 46: 2101–2104, 1986

    Google Scholar 

  8. Barba D, Saris SC, Holder C, Rosenberg SA, Oldfield EH: Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J Neurosurg 70: 175–182, 1989

    Google Scholar 

  9. Merchant RE, Grant AJ, Merchant LH, Young HF: Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant Interleukin-2. Cancer 62: 665–671, 1988

    Google Scholar 

  10. Ingram M, Buckwalter JG, Jacques DBS, Freshwater DB, Abts RM, Techy GB, Miyagi K, Shelden CH, Rand RW, English LW: Immunotherapy for malignant glioma: an interim report on survival. Neurological Res 12: 265–273, 1990

    Google Scholar 

  11. Kitahara T, Watanabe O, Yamaura A, Makino H, Watanabe T, Suzuki G, Okumura K: Establishment of Interleukin-2 dependent cytotoxic T lymphocytes cell line specific for autologous brain tumor and its intracranial administration for therapy of the tumor. J Neuro-Oncology 4: 329–336, 1987

    Google Scholar 

  12. Yoshida S, Tanaka R, Takai N, Ono K: Adoptive immunotherapy with LAK cells and Interleukin-2 in the treatment of recurrent malignant gliomas. Current Therapeut Res 47: 654–665, 1990

    Google Scholar 

  13. Kempf RA, Mitchell MS: Effects of chemotherapeutic agents on the immune response. Cancer Investigation 2: 459–466, 1984

    Google Scholar 

  14. North RJ: Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med 55: 1063–1074, 1982

    Google Scholar 

  15. Berd D, Mastrangelo MJ: Effect of low dose cyclophosphamide on the immune system of cancer patients. Reduction of T-suppressor function without depletion of the CD8+ subset. Cancer Res 47: 3317–3321, 1987

    Google Scholar 

  16. Berd D, Mastrangelo MJ: Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cells. Cancer Res 48: 1671–1675, 1988.

    Google Scholar 

  17. Isaacs JT: Relationship between tumor size and curability of prostatic cancer by combined chemo-hormonal therapy in rats. Cancer Res 49: 6290–6294, 1989

    Google Scholar 

  18. Mitchell MS: Combining chemotherapy with biological response modifiers in treatment of cancer. J Natl Cancer Inst 80: 1445–1450, 1988

    Google Scholar 

  19. Kedar E, Ben-Aziz R, Epstein E, Leshem B: Chemoimmunotherapy of murine tumors using interleukin-2 (IL-2) and cyclophosphamide. Cancer Immunol Immunother 29: 74–78, 1989

    Google Scholar 

  20. Papa MZ, Yang JC, Vetto JT, Shiloni E, Eisenthal A, Rosenberg SA: Combined effects of chemotherapy and interleukin-2 in the therapy of mice with advanced pulmonary tumors. Cancer Res 48: 122–129, 1988

    Google Scholar 

  21. Lee K, O'Donnell RW, Marquis D, Cockett AT: Eradication of palpable intradermal murine bladder tumors by systemic interleukin-2 and cyclophosphamide in C3H mice. J Biol Response Mod 7: 32–42, 1988

    Google Scholar 

  22. Ootsu K, Gotoh K, Houkan T: Therapeutic efficacy of human recombinant interleukin-2 (TGP-3) alone or in combination with cyclophosphamide and immunocompetent cells in allogeneic, semi-syngeneic, and syngeneic murine tumors. Cancer Immunol Immunother 30: 71–80, 1989

    Google Scholar 

  23. Silagi S, Schaefer AE: Successful immunotherapy of mouse melanoma and sarcoma with recombinant interleukin-2 and cyclophosphamide. J Biol Response Mod 5: 411–422, 1986

    Google Scholar 

  24. Mule JJ, Rosenberg SA: Combination cytokine therapy: experimental and clinical trials. In: DiVita VTJr, Hellman S, Rosenberg SA (eds) Biologic Therapy of Cancer. J.B. Lippincott Co., Philadelphia, 1991, pp 393–416

    Google Scholar 

  25. Kedar E, Ben-Aziz R, Shiloni E; Therapy of advanced solid tumors in mice using chemotherapy in combination with interleukin-2 with and without lymphokine-activated killer cells. Israel J Med Sci 24: 494–504, 1988

    Google Scholar 

  26. Rosenberg SA, Spiess P, Lafreniere R: A new approach to the adoptive immunotherapy of cancer with tumor infiltrating lymphocytes. Science 233: 1318–1321, 1986

    Google Scholar 

  27. Eggermont AMM, Sugarbaker PH: Efficacy of chemoimmunotherapy with cyclophosphamide, interleukin-2 and lymphokine activated killer cells in an intraperitoneal murine tumour model. Br J Cancer 58: 410–414, 1988

    Google Scholar 

  28. Cheever MA, Greenberg PD, Fefer A: Specific adoptive therapy of established leukemia with syngeneic lymphocytes sequentially immunizedin vivo andin vitro and non-specifically expanded by culture with interleukin-2. J Immunol 126: 1318–1322, 1981

    Google Scholar 

  29. Cheever MA, Greenberg PD, Fefer A, Gillis S: Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes byin vivo administration of purified interleukin 2. J Exp Med 155: 968–980, 1982

    Google Scholar 

  30. Greenberg PD: Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 49: 281–355, 1991

    Google Scholar 

  31. Kruse CA, Lillehei KO, Mitchell DH, Kleinschmidt-De-Masters BK, Bellgrau D: Analysis of interleukin-2 and various effector cell populations in adoptive immunotherapy of 9L rat gliosarcoma: allogeneic cytotoxic T lymphocytes prevent tumor take. Proc Natl Acad Sci (USA) 87: 9577–9581, 1990

    Google Scholar 

  32. Tzeng J-J, Barth RF, Clendenon NR, Gordon WA: Adoptive immunotherapy of a rat glioma using lymphokine-activated killer cells and interleukin-2. Cancer Res 50: 4338–4343, 1990

    Google Scholar 

  33. Yamasaki T, Handa H, Yamashita J, Watanabe Y, Namba Y, Hanaoka M: Specific adoptive immunotherapy with tumor-specific cytotoxic T lymphocyte clone for murine malignant gliomas. Cancer Res 44: 1776–1783, 1984

    Google Scholar 

  34. Takai N, Tanaka R, Yoshida S, Hara N, Saito T:In vivo andin vitro effect of adoptive immunotherapy of experimental murine brain tumors using lymphokine-activated killer cells. Cancer Res 48: 2047–2052, 1988

    Google Scholar 

  35. Mulvin DW, Kruse CA, Mitchell DH, Marcell T, James GT, Johnston M: Lymphokine activated killer cells with Interleukin-2: Dose toxicity and localization in isolated perfused rat lungs. Mol Biother 2: 38–43, 1990

    Google Scholar 

  36. Bellgrau D, Lagarde A-C: Cytotoxic T cell precursors with low-level CD8 in the diabetes-prone biobreeding rat: implications for generation of an autoimmune T-cell repertoire. Proc Natl Acad Sci (USA) 87: 313–317, 1990

    Google Scholar 

  37. Kruse CA, Mitchell DH, Lillehei KO, Johnson SD, McCleary EL, Moore GE, Waldrop S, Mierau GW: Interleukin-2 activated lymphocytes from brain tumor patients. A comparison of two preparations generatedin vitro. Cancer 64: 1629–1637, 1989

    Google Scholar 

  38. Ballas ZK: Lymphokine-activated killer (LAK) cells I. Differential recovery of LAK, natural killer cells, and cytotoxic T lymphocytes after a sublethal dose of cyclophosphamide. J Immunol 137: 2380–2384, 1986

    Google Scholar 

  39. Kim R, Lafreniere R, Borkenhagen K, Bryant LD: Induction of cytotoxicity from fresh splenocytes afterin vivo administration of cyclophosphamide. Cancer Immunol Immunother 30: 283–288, 1989

    Google Scholar 

  40. Cotran RS, Pober JS, Gimbrone MAJr, Springer TA, Wiebke EA, Gaspari AA, Rosenberg SA, Lotze MT: Endothelial activation during interleukin 2 immunotherapy. A possible mechanism for the vascular leak syndrome. J Immunol 139: 1883–1888, 1987

    Google Scholar 

  41. Rosenstein M, Ettinghausen SE, Rosenberg SA: Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J Immunol 137: 1735–1742, 1986

    Google Scholar 

  42. Dropcho EJ, Mahaley MS: Chemotherapy for malignant gliomas in adults. In: Thomas DGT (ed) Neuro-oncology. Johns Hopkins University Press, Baltimore, 1990, pp 222–241

    Google Scholar 

  43. Yung WKA, Levin VA: Chemotherapy: current and future role and expectations. In: Apuzzo MLJ (ed) Malignant Cerebral Glioma. AANS Publications, Park Ridge, IL, 1990, pp 207–216

    Google Scholar 

  44. Powrie F, Mason D: Subsets of rat CD4+ T cells defined by their differential expression of variants of the CD45 antigen: developmental relationships andin vitro andin vivo functions. Curr Top Microbiol Immunol 159: 79–96, 1990

    Google Scholar 

  45. Merchant RE, Fontana A, Nelson ATJr, Young HF: Mitogen-activated lymphocytes of normals and glioma patients produce factors with anti-glioblastoma activityin vitro. J Neuroimmunol 11: 1–14, 1986

    Google Scholar 

  46. Atkinson LL, Merchant RE, Ghatak NR, Young HF: Sterile abscesses in glioma patients treated by intraparenchymal injection of lymphokine-activated killer cells and recombinant interleukin-2. Neurosurgery 25: 805–810, 1989

    Google Scholar 

  47. Kolitz JE, Wong GY, Weite K, Merluzzi VJ, Engert A, Bialas T, Polivka A, Bradley EC, Konrad M, Gnecco C, Oettgen HF, Mertelsmann R: Phase I trial of recombinant interleukin-2 and cyclophosphamide: augmentation of cellular immunity and T-cell mitogenic response with longterm administration of rIL-2. J Biol Response Mod 7: 457–472, 1988

    Google Scholar 

  48. Croghan M, Hersh EM, Taylor C, Meyskens F, Dalke P, McDonald L, Gardern S, Rudolph A: Phase I–II study of low dose cytoxan and recombinant interleukin-2 (IL-2) for the treatment of disseminated carcinoma (Abstract). Proc Am Soc Clin Oncol 8: 180, 1989

    Google Scholar 

  49. Rubin JT, Elwood LJ, Rosenberg SA, Lotze MT: Immunohistochemical correlates of response to recombinant interleukin-2 based immunotherapy in humans. Cancer Res 49: 7086–7092, 1989

    Google Scholar 

  50. Mitchell MS, Kempf RA, Harel W, Shau H, Boswell WD, Lind S, Bradley EC: Effectiveness and tolerability of lowdose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma. J Clin Oncol 6: 409–424, 1988

    Google Scholar 

  51. Rosenberg SA: Clinical immunotherapy studies in the surgery branch of the U.S. National Cancer Institute: brief review. Cancer Treatment Reviews 16: 115–121, 1989

    Google Scholar 

  52. Topalian SL, Solomon D, Avis FP, Chang AE, Freerksen DL, Linehan WM, Lotze MT, Robertson CN, Seipp C, Simon P, Rosenberg SA: Immunotherapy of patients with advanced cancer using tumor infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J Clin Oncol 6: 839–853, 1988

    Google Scholar 

  53. Kohler PC, Hank JA, Minkoff DG, Sondel PM: Clinical adoptive chemoimmunotherapy with allogeneic alloactivated HLA-haploidentical lymphocytes: controlled induction of graft-versus-host-reactions. Cancer Immunol Immunother 26: 74–82, 1988

    Google Scholar 

  54. Naganuma H, Kimurat R, Sasaki A, Fukamachi A, Nukui H, Tasaka K: Complete remission of recurrent glioblastoma multiforme following local infusions of lymphokine activated killer cells. Case report. Acta Neurochir (Wien) 99: 157–160, 1989

    Google Scholar 

  55. Nitta T, Sato K, Yagita H, Okumura K, Ishii S: Preliminary trial of specific targeting therapy against malignant glioma. The Lancet 335: 368–370, 1990

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, University of Colorado Health Sciences Center, 80262, Denver, Colorado, USA

    Carol A. Kruse, Dawn H. Mitchell, Qingzhong Kong & Kevin O. Lillehei

  2. Department of Pathology, University of Colorado Health Sciences Center, 80262, Denver, Colorado, USA

    Carol A. Kruse & Bette K. Kleinschmidt-DeMasters

  3. Department of Microbiology/Immunology, University of Colorado Health Sciences Center, 80262, Denver, Colorado, USA

    Donald Bellgrau, James M. Eule & Jose R. Parra

Authors
  1. Carol A. Kruse
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dawn H. Mitchell
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bette K. Kleinschmidt-DeMasters
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Donald Bellgrau
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. James M. Eule
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jose R. Parra
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Qingzhong Kong
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kevin O. Lillehei
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kruse, C.A., Mitchell, D.H., Kleinschmidt-DeMasters, B.K. et al. Systemic chemotherapy combined with local adoptive immunotherapy cures rats bearing 9L gliosarcoma. J Neuro-Oncol 15, 97–112 (1993). https://doi.org/10.1007/BF01053931

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01053931

Key words

Search

Navigation